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ABSTRACT
The economic importance of soybean (Glycine max) as a foodstuff has, in recent years, 
been supplemented by its importance as a source of bioactive compounds. Two of these 
compounds, the Bowman-Birk protease inhibitor (BBI) and the peptide lunasin, exhibit anti-
cancer properties, and clinical studies suggest that the two may act in a complementary fashion. 
The present work surveys the levels of these two compounds across a time course of soybean 
development, a number of diverse soybean genotypes from the USDA Soybean Germplasm 
Collection, and a collection of soybean lines grown at Urbana and Bellflower, IL in the summer 
of 2012. Concentrations of BBI measured across mature lines in the study ranged from .101 to 
.38 mg/g defatted seed, while concentrations of lunasin ranged from 1.06 to 6.12 mg/g defatted 
seed. BBI and lunasin were significantly correlated through seed development (p = .0097), but 
concentrations of the compounds were not related in mature seeds. Genotype and the interaction 
of genotype by environment were found to significantly impact BBI (p = .03; p = .01), and this 
interaction effect was found to vary in direction depending on genotype. Environment (p = .03) 
and genotype had significant effects (p = .03; p < .01) on lunasin. Soil moisture may be the most 
important environmental factor in determining lunasin concentrations.
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1Literature Review
The domesticated soybean (Glycine max (L.) Merr) of the family Leguminosae, 
subfamily Papilionoideae, and tribe Phaseoleae (Doyle & Doyle, 1993), is among the most 
important agricultural crops in the United States. In 2011, approximately 74 million acres of 
soybeans were planted in the United States, yielding a total of over 3 billion bushels with an 
economic value of nearly 37 billion dollars (USDA ERS, 2012). This value is primarily derived 
from the protein and oil of the soybean seed; on a 13% seed moisture basis, the average protein 
content of US soybeans grown from 1986 to 2003 was 35.5%, while the average oil content was
18.6% (Brumm & Hurburgh, 2006). Soybean meal, a product with nearly 13 billion dollars in 
combined domestic and export sales in 2011 (USDA ERS, 2012), is important as a source of 
high-protein livestock feed, and soybean oil has a variety of industrial, fuel, and food 
applications (Clemente & Cahoon, 2009). Soybean has also been utilized as a high-protein 
vegetable food for human consumption since its original domestication in China in 
approximately the 11th century BCE (Hymowitz, 1970). Indeed, the first soybeans brought to the 
United States by Samuel Bowen in 1765 were grown for the production of soy sauce and 
soybean noodles (Hymowitz and Harlan, 1983). More recently, health studies on the components 
of the soybean seed, especially several of its bioactive compounds, have greatly increased the 
demand for soy products as functional human foodstuffs. 
Soy fiber, for example, has been investigated as a functional component of soy foods. 
Soy hulls and soy flour have different fiber profiles: the fiber of hulls is primarily cellulose and 
hemicellulose (Erdman & Weingartner, 1981), while that of flour is primarily non-cellulosic (Lo, 
1989). Up to 93% of cotyledon-derived soy fiber is digestible in humans (McNamara et al., 
1986), which suggests that the fiber may be readily metabolized. Indeed, soy fiber has been 
2demonstrated in several studies to have superior functional properties for human health, reducing 
LDL levels and improving glucose tolerance to a greater degree than comparable fiber sources 
(Erdman & Weingartner, 1981; Tsai et al., 1983; Lo et al., 1986). The reduction in LDL is 
especially vital to the cardiovascular system, as it prevents the buildup of arterial plaque that may 
lead to blockage and myocardial infarction (de Lemos et al., 2010). Bowel function in humans is 
also improved by soy fiber, as indicated by increases in stool weight and decreases in 
gastrointestinal transit time (Slavin, 1991) after soy fiber supplementation.
Soybean and soy foods have also been recognized as significant sources of isoflavones 
(Wang & Murphy, 1994), plant-derived compounds that can function as estrogen analogues in 
mammals like humans (Setchell, 1998). The first soy isoflavone to be discovered was genistin 
(Walter, 1941), and further work identified two others, daidzin and glycitin (Naim et al., 1974), 
along with different naturally-occurring forms for each. These compounds can be processed into 
bioactive forms by human gut flora (Setchell et al., 2002), and both the raw compounds and the 
resulting metabolites have been implicated as beneficial against a number of diseases (Tham et 
al., 1998). For example, soy isoflavones have been shown to bind with osteoblast estrogen 
receptors and stimulate insulin-like growth factor production (Arjmandi & Smith, 2002), 
providing protection against osteoporosis. However, individual metabolic differences may 
mediate the effectiveness of isoflavones against bone resorption: a recent study indicated that 
postmenopausal women capable of metabolizing dietary isoflavones into equol are at 
significantly less risk for osteoporosis than women who are unable to process the compounds 
(Weaver & Legette, 2010).
Soy isoflavones have attracted additional interest for their impacts on cardiovascular 
health, particularly atherosclerotic risk. Three months of a high-isoflavone diet were shown to 
3reduce low-density lipoprotein (LDL) and the LDL/HDL ratio in the plasma of postmenopausal 
women (Wangen et al., 2001), and two months of a diet containing isoflavone-enriched pasta 
improved both serum lipid characteristics and arterial stiffness (Clerici et al., 2007). It is worth 
noting that the previous study also considered equol metabolic ability; the benefits of isoflavones 
were evident in both equol-producing and equol-deficient subjects, although they were greatest 
among equol producers. Primate studies have suggested other mechanisms for the cardiovascular 
benefits of isoflavones, including antioxidative activity and antiproliferative impacts on smooth 
muscle cells (Anthony et al., 1998). Evidence linking soy isoflavones to a reduced risk of breast 
cancer in human populations has been reported (Yamamoto et al., 2003), although these effects 
are less established than the other benefits of soy. Laboratory work to confirm the anticancer 
effects of isoflavones has yielded conflicting results, with studies that suggest isoflavones both 
stimulate tumor growth (Ju et al., 2001) and prevent immunosuppression of cancer cells (Jiang et 
al., 2008). Whether soy isoflavones are beneficial or harmful to cancer may be dose-dependent, 
as high levels of these compounds are generally observed to inhibit tumor formation and growth 
(Wood et al., 2006; Zhang et al., 2012).
Diets high in soy protein also have demonstrated benefits for a number of health markers. 
A meta-analysis of 38 clinical soy protein trials detected significant decreases in total 
cholesterol, triglycerides, and LDL levels in comparison with control diets (Anderson et al., 
1995). The 7S-globulin storage protein is thought to be at least partially responsible for these 
changes, as demonstrated by a mouse study in which the protein reduced triglyceride levels in 
comparison with casein or glycinin diets (Moriyama et al., 2004). This reduction was associated 
with the upregulation of beta-oxidation and downregulation of fatty acid synthase, as well as 
with reductions in serum glucose and insulin. Soy protein may positively impact bone retention, 
4but this effect is most likely due to the isoflavones present in a soy diet, as previously discussed. 
In one clinical study, a year of soy protein supplementation improved a number of bone health 
markers in postmenopausal women, but it did not lead to a reduction in actual bone loss 
(Arjmandi et al., 2005). Similarly, a six-month clinical study in postmenopausal women only 
detected the protective effects of a soy protein diet against spinal bone loss when the diet was 
supplemented with higher isoflavone levels (Potter et al., 1998). Finally, a recent meta-analysis 
associated soy protein intake with reduced risk for a number of cancers, including prostate, 
breast, and colon cancer (Badger et al., 2005). The same authors confirmed these effects for 
breast and colon cancers in a rat model, and microarray analysis revealed that the soy diet 
downregulated a number of genes involved in the activation pathway for a common carcinogen. 
From a nutritional standpoint, soybean protein is generally considered to be a “complete” 
protein, as it contains adequate levels of all essential amino acids (Young, 1991). Human feeding 
studies have demonstrated the sufficiency of soy as the lone protein source (Beer et al., 1989), 
alleviating early concerns about the plant’s relatively low levels of methionine. Levels of this 
essential sulfur-containing amino acid have been shown to vary across the US soybean 
production region, with higher levels detected in the center of the region than in the northern or 
southern edges (Karr-Lilienthal et al., 2005). Methionine variation is thought to be due primarily 
to differences in the accumulation of the 11S glycinin storage proteins (Mahmoud et al., 2006), 
which are associated with both genetic and environmental factors (Fehr et al., 2003).
The majority of the protein present in soybean is storage protein. Approximately 34% of 
the protein is in the 11S fraction as glycinin, while approximately 27% of the protein is present 
in the 7S fraction as β-conglycinin (Petruccelli & Anon, 1995). The relative amounts of these 
storage proteins vary among genotypes, as do the proportions of the subunits that compose each 
5storage protein (Riblett et al., 2001). Interestingly, the proportion of the β subunit of β-
conglycinin is lower in modern soybean cultivars than in ancestral varieties, and as this subunit 
contains no sulfur-containing amino acids, the protein quality of soybean has been improved 
over time (Mahmoud et al., 2006). A number of other storage globulins, such as γ-conglycinin 
and the basic 7S globulin, are present in less abundant levels in the 11S and 7S protein fractions 
(Thanh et al., 1975). The most abundant functional proteins in the seed include cytochrome c, 
lipoxygenase, β –amylase, hemagglutinin, and the soybean trypsin inhibitors (Wolf, 1970): the 
Kunitz trypsin inhibitor (KTI) (Kunitz, 1945) and the Bowman-Birk protease inhibitor (BBI) 
(Bowman, 1946; Birk, 1985). 
Soybean protease inhibitors
The Kunitz trypsin inhibitor was first described by Kunitz in 1945 using X-ray 
crystallography. Subsequent work showed the protein to be composed of 181 amino acids (Koide 
et al., 1972), with a single active site that inhibits both trypsin and α-chymotrypsin 
(Bidlingmeyer et al., 1972). The genetics of KTI inheritance are somewhat complex; early 
classical genetic work revealed the presence of four distinct alleles at a single locus (Orf & 
Hymowitz, 1979). Three of these alleles are codominant and encode minor variations of the 
inhibitor, designated Tia, Tib, and Tic, which are distinguishable through electrophoresis (Orf & 
Hymowitz, 1977). The amino acid sequences of these variants are all of the same length, and Tib
and Tic both differ from the more prevalent Tia only by the order of a single amino acid (Kim et 
al., 1985). These small differences do appear to have functional relevance: Tib is significantly 
less effective at inhibiting trypsin than the other variants, and while Tic is slightly more effective 
than Tia, it is also less thermally stable (Freed & Ryan, 1980), providing a possible selective 
pressure for the Tia allele among soybean accessions. Shortly after the discovery of these 
6variants, near-isogenic lines (NILs) derived from the cultivar “Williams” that were homozygous 
for each variant were developed and released as L82-2024 (Tib ) and L82-2051 (Tic) (Bernard & 
Hymowitz, 1986a). 
The fourth allele, designated ti, codes for an absence of KTI and is recessive to each of 
the three variant alleles (Orf & Hymowitz, 1979). This allele was quite uncommon among the 
accessions screened in this early work, with only two Korean plant introductions (PIs) possessing 
the null (Hymowitz, 1986). One of these accessions, PI 157440, was used to develop three NILs 
with the cultivars “Williams 82” (L81-4590), “Clark 63” (L81-4871), and “Amsoy 71” (L83-
4387) that were homozygous for the KTI null (Bernard & Hymowitz, 1986b). After further 
testing and development, the NIL derived from Williams 82 was released commercially as the 
cultivar “Kunitz” (Bernard et al., 1991). Although no further cultivars containing the KTI null 
have been released commercially, a number of experimental lines with double nulls were 
developed that combined the KTI null with nulls for lectin, lipoxygenase-1, μ-amylase, and 
urease (Prischmann & Hymowitz, 1988).
Further genetic study has revealed at least 10 genes in the soybean genome that bear 
close similarity to the primary Kunitz gene (Jofuku & Goldberg, 1989). However, most of the 
genes appear to code for proteins that lack inhibitory activity, suggesting that a single gene, KTI-
3, accounts for most of the observed protein and activity. Agricultural species besides soybean 
that have been shown to contain members of the Kunitz family include Populus tremuloides 
(quaking aspen) (Haruta et al., 2001), Cicer arietinum (chickpea) (Srinivasan et al., 2005), and 
Populus trichocarpa × Populus deltoides (hybrid poplar) (Major & Constabel, 2008).
BBI was first detected by Bowman in 1946, who distinguished it from the previously 
known KTI, but the compound was largely ignored until the 1960s. Much of the early 
7purification and characterization work was conducted by Birk and colleagues (Birk, 1961; Birk 
et al., 1963), and in recognition of the efforts of both scientists, the name “Bowman-Birk 
inhibitor” was given to the protein (Steiner & Frattali, 1969). BBI consists of 71 amino acids, 
including 14 half-cystine residues (Odani and Ikenaka, 1972), and contains two active sites, one 
inhibiting trypsin and the other inhibiting chymotrypsin (Odani and Ikenaka, 1973). These two 
sites are present in almost symmetrical halves of the molecule, yielding a characteristic “double 
headed” molecular structure (Qi et al., 2005). Further work revealed that the initial BBI 
discovered by Bowman and Birk was only the most prevalent component of an entire class of 
protease inhibitors present in soybean and other flowering plants. Soybean contains this “major” 
or “classical” BBI along with 9 similar proteins (isoinhibitors) (Tan-Wilson et al., 1985), 
although only 4-7 isoinhibitor forms are found in any particular accession. Despite the similar 
targets of BBI and KTI, there is little to no amino acid sequence similarity observed between the 
two proteins. There have also been no nulls detected for the major BBI in either domesticated 
soybean or its wild ancestor, Glycine soja (Domagalski et al., 1992). Significant variation for the 
compound nonetheless exists across soybean accessions (Gladysheva et al., 2000; Pesic et al., 
2007), and growing conditions have been shown to impact BBI levels (Krishnan et al., 2012). 
BBI nulls have been detected in many of the perennial Glycine species. An initial survey 
of Glycine diversity using ELISA found BBI nulls in G. curvata Tind., G. cyrtoloba Tind., G. 
latifolia (Benth.) Newell & Hymowitz, G. microphylla (Benth.) Tind., G. tabacina (Labill.) 
Benth., and G. tomentella Hayata (Domagalski et al., 1992). Kollipara et al. (1995) confirmed 
these previously reported nulls and also found BBI nulls in the recently discovered species G. 
albicans Tind. and Craven. Interestingly, the presence or absence of BBI appeared to be linked 
with the intergenomic relationships of the genus: species with B- or C-genomes were BBI null, 
8while species with A-, E-, and F-genomes were BBI positive. Both BBI null and BBI positive 
accessions were present in 2n = 40 G. tomentella accessions and 2n = 80 G. tabacina. Very little 
work has been conducted to determine the causes or inheritance patterns of these BBI nulls. A 
genetic study in G. tomentella demonstrated that the BBI null allele was recessive and 
monogenic; the locus was weakly linked to another protease inhibitor (Kollipara et al., 1996). 
Inheritance was not studied in G. microphylla, but cloning of the BBI null allele revealed a four-
nucleotide deletion that caused a frameshift in the coding region, presumably preventing a 
buildup of the product in the seed (Krishnan & Kim, 2003). None of the other perennial Glycine 
BBI nulls have been characterized. 
The DNA sequence for the major BBI in domesticated soybean has been cloned, along 
with those for several of its isoinhibitors (Baek et al., 1994), and allelic variation has been 
observed within the family (Wang et al., 2008). In silico analysis has identified putative 
sequences for the remaining soybean BBI isoinhibitors (de Almeida Barros et al., 2012). 
Previous work shows that BBI appears in soybean seeds 7 weeks after flowering, increases 
through maturity, and remains in the mature seed (Park et al., 2005). Members of the BBI family 
have been found in Triticum aestivum (common wheat) (Odani et al., 1986), Coix lacryma-jobi
(Job’s tears) (Ary et al., 1988), Setaria italica (foxtail millet) (Tashiro et al., 1990), Vicia faba
(broad beans) (Ye et al., 2001), Oryza sativa (rice) (Qu et al., 2003), Hordeum vulgare (barley) 
(Park et al., 2004), Lens culinaris (lentils) (Caccialupi et al., 2010), and Lathyrus sativus (grass 
pea) (De Paola et al., 2012), among other species.
The soybean protease inhibitors have been shown to have antinutritional effects in several 
animal species (Liener, 1994). Early studies on rats (Klose et al., 1946) and chicks (Ham et al., 
1945) demonstrated that animals raised on diets containing raw soybean meal performed more 
9poorly than those fed diets without raw soybeans. The inhibitors were shown to cause 
hypertrophy of the pancreas and a proliferation or hyperplasia of the acinar cells in the pancreas 
(Chernick et al., 1948) in response to reduced digestive enzyme activity. An enlarged and 
overactive pancreas diverts resources from the rest of the organism to produce more digestive 
enzymes (Lyman and Lepkovsky, 1957), retarding its growth. Additionally, the overactivity of 
the acinar cells causes them to become susceptible to certain carcinogenic agents, including di(2-
hydroxypropyl)nitrosamine (McGuinness and Wormsley, 1986). Nearly all soybean products are 
processed using heat to denature these inhibitors (Anderson and Wolf, 1995). However, this 
process is not completely effective at inactivating the proteins, and anywhere from 5-20% of the 
inhibitory action of raw soybean flour is present in heated or toasted flours (Friedman & 
Brandon, 2001). The human pancreas has been shown to increase its output of digestive enzymes 
in response to the reduction of trypsin and chymotrypsin activity caused by the Bowman-Birk 
inhibitor (Liener et al., 1988). Such feedback effects may have detrimental impacts in humans, as 
they do in rats, but the clinical evidence on this point is rather sparse.
More recent research has suggested that these protease inhibitors may actually cause 
beneficial effects in humans. The KTI from soybeans has been shown to suppress the metastasis 
of human ovarian cancer by preventing the expression of a signaling protein in tumor cells 
(Kobayashi et al., 2004). This inhibitor also downregulates the production of a tumor necrosis 
factor in human keratinocytes, possibly offering protection against skin cancers caused by 
ultraviolet radiation (Kobayashi et al., 2005). Mice fed a diet supplemented with KTI showed 
significantly less inflammation due to lipopolysaccharides than mice on a control diet 
(Kobayashi et al., 2005), and similar effects have been observed for a number of proteins with 
Kunitz-type active sites (Shigetomi et al., 2010), suggesting that KTI may be valuable for the 
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treatment of arthritis, heart disease, asthma, and other inflammation-related diseases. BBI 
suppresses radiation-induced carcinogenesis in a number of different cell types (Yavelow et al., 
1985; Kennedy et al., 2006), prevents the growth and survival of prostate cancer cells 
(Malkowicz et al., 2001; Kennedy and Wan, 2002), and inhibits the esophageal carcinogenic 
effects of N-nitrosos-methylbenzylamine (von Hofe et al., 1991). Interestingly, BBI has also 
been found to reduce the negative effects of muscle atrophy by buffering against oxidant activity 
(Arbogast et al., 2007), a property that may be useful to astronauts on lengthy space journeys.
BBI may be important not only due to its own beneficial effects but also due to the role it plays 
in protecting another soybean compound, lunasin, from digestion. 
Lunasin peptide
Lunasin is a bioactive peptide, originally discovered in soybean, with cancer-preventative 
properties (de Lumen, 2005). The peptide was first detected as part of a larger hydrophobic 
protein and was noted for its poly (L-aspartic acid) tail (Odani et al., 1987; Odani et al., 1987). 
The gene with which this peptide was associated was not determined for another decade, until a 
team at the University of California, Berkeley purified a large methionine-rich protein from 
soybean (Revilleza et al., 1996) and used its amino acid sequence to clone a cDNA for a 
posttranslationally processed 2S albumin (Gm2s-1) (Galvez et al., 1997). This cDNA not only 
encoded the methionine-rich protein, but also a signal peptide, a small subunit (lunasin), and a 
linker peptide. As the experimenters attempted to isolate lunasin from Escherichia coli cells 
transformed with the small subunit coding region of the Gm2s-1 cDNA, they noticed that the 
transformed bacteria exhibited reduced growth and elongated filaments, signs of disrupted 
mitosis (Galvez and de Lumen, 1999). E. coli transformed with cDNAs in which the polyaspartyl 
end of the lunasin had been deleted, in contrast, showed normal growth patterns. Further work 
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demonstrated that mammalian cancer cells transfected with the lunasin-coding cDNA also 
showed disrupted mitotic patterns; again, cDNAs with the deletion generated no effect. This anti-
mitotic effect was cytotoxic in many cases, an effect hypothesized to be caused by the inability 
of the cell lines to accommodate high genome dosages and the disruption of spindle formation 
(Galvez and de Lumen, 1999). These modes of action are similar to those of the taxanes, an 
established class of anti-cancer drugs (Rowinsky et al., 1992), and the promise of the compound 
as a possible cancer treatment led de Lumen and Galvez to patent the lunasin peptide from 
soybean in 2000.
The primary structure of lunasin consists of 43 amino acids: it contains a polyaspartyl tail 
of 9 aspartic acid residues at the carboxyl end, an Arg-Gly-Asp cell adhesion motif, and a helical 
region with structural homology to a conserved region present across chromatin-binding proteins 
(Galvez et al., 2001). As previously noted, the lunasin cDNA has been cloned, and this sequence 
maps onto the Williams 82 genome chromosome 13 between the bases 37700716 and 37701192 
(Grant et al., 2010). This sequence is within 0.2 Mbp of the molecular marker Satt254. Lunasin 
RNA is expressed in the soybean from 3 weeks after flowering onward, and this expression only 
occurs in the cotyledon (de Lumen et al., 1999); no lunasin RNA is found in leaf, stem, or root 
tissue. The compound itself, however, has not been shown to appear in detectable quantities until 
5 weeks after flowering (Jeong et al., 2003). Levels of lunasin have been observed to increase as 
the seed approaches maturity, and some lunasin is maintained in the mature seed (Park et al., 
2005).
To date, there have been only two studies examining variation among soybean genotypes 
for lunasin content. An initial survey quantified the amount of lunasin present in 144 soybean 
lines, covering all 13 maturity groups (MG) and a number of geographical origins (de Mejia et 
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al., 2004). A range of 1 to 13 mg lunasin/g defatted flour was detected, with the highest lunasin 
levels recorded in accessions from MG IX and X. However, the samples analyzed in this study 
were taken directly from the USDA Soybean Germplasm Collection, which is maintained by 
growing out a portion of the accessions every year. Therefore, the environmental conditions 
under which the lines of the study had been grown were not consistent across entries, and year 
and location effects were confounded with the effect of the genotype. A subsequent experiment 
grew 5 soybean accessions under a number of controlled temperature and moisture conditions in 
an attempt to separate out environmental variability (Wang et al., 2008). Significant genotypic 
differences did exist between the cultivars, but temperature also had a significant effect, with 
soybeans grown under low (13/23°C night/day) or intermediate (18/28°C night/day) 
temperatures during the R6 and subsequent growth stages containing more lunasin than soybeans 
grown at high (23/33°C night/day) temperatures. Soil moisture had no significant main effect but 
was implicated in a number of interactions with cultivar and temperature.
Although first isolated in soybean, lunasin has subsequently been isolated in barley 
(Jeong et al., 2002), common wheat (Jeong et al., 2007), Solanum nigrum (black nightshade) 
(Jeong et al., 2007), Amaranthus hypochondriacus (amaranth) (Silva-Sanchez et al., 2008), 
Secale cereale (rye) (Jeong et al., 2009), Panicum miliaceum (common millet) (Park et al., 
2009), and × Triticosecale (triticale) (Nakurte et al., 2012). Of these sources, soybean appears to 
have the highest lunasin quantities, although triticale contains comparable amounts (Muceniece 
et al., 2012). The majority of medical studies involving the peptide, however, have been 
conducted with synthetic lunasin, due to the availability of its primary sequence. The large-scale 
production and isolation of natural lunasin from soybeans, while suggested by Jeong et al.
(2003), has only recently been made feasible. A commercial-scale chromatography and 
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ultrafiltration method is now available to isolate lunasin from soy flour (Seber et al., 2012), and 
the production of the peptide in recombinant E. coli, while still somewhat hindered by the 
mitotic abnormalities observed in early experiments, has significantly improved (Liu and Pan, 
2010; Kyle et al., 2012). Another recent study presents an unusual method of lunasin enrichment 
for a variety of flours through the use of sourdough lactic acid bacteria fermentation (Rizzello et 
al., 2012), although this strategy might be more suited for the nutraceutical market than for 
scientific or medicinal production.
The first in vivo demonstration of lunasin’s cancer-preventative properties was conducted 
in the SENCAR (SENsitive to CARcinogenesis) mouse skin tumor model (Galvez et al., 2001). 
This study used topically-applied lunasin to achieve significant reductions in tumor formation in 
comparison with a control group. Lunasin prevented the formation of foci in the fibroblast cells 
(Lam et al., 2003). Both cells treated with chemical carcinogens and those transformed with the 
E1A oncogene were effectively suppressed by the peptide, while control cells were unaffected. 
Established cancer cell lines, however, were also unaffected by lunasin. Subsequent studies 
suggested that lunasin may prevent carcinogenesis through binding to the deacetylated histones 
of cancerous cells, inhibiting reacetylation and causing the cell to undergo apoptosis (Jeong et 
al., 2002; Jeong et al., 2007).  Several more detailed apoptotic mechanisms have been observed 
in more recent studies. In leukemia cells, for example, lunasin promotes apoptosis through the 
activation of the caspase-3 (Cysteine-ASPartic acid proteASE) protein (de Mejia et al., 2010), 
and in colon cancer cells, lunasin induces the expression of a pro-apopotic clusterin isoform (Dia 
and de Mejia, 2010). Lunasin has been found to prevent the adhesion of metastatic colon cancer 
cells to the extracellular matrix and to healthy cells through regulatory changes in a number of 
relevant genes, such as those coding for integrins and the endothelial-leukocytre adhesion 
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molecule 1 (SELE) (Dia and de Mejia, 2011). Additionally, lunasin appears to have a synergistic 
effect with aspirin, inducing highly significant levels of apoptosis in breast cancer (Hsieh et al., 
2010) and fibroblast (Hsieh et al., 2011) cells by arresting them at complementary phases in the 
cell cycle. Although no in vivo clinical trials of the peptide have been conducted in humans, it 
has been demonstrated that the consumption of soy protein does provide bioavailable lunasin to 
humans (Dia et al., 2009).
These promising medicinal qualities, combined with the availability of commercial-scale 
purification techniques, make high-lunasin soybean lines greatly desirable to the health market. 
The peptide is already being marketed as a fortifying ingredient in a number of soy protein 
formulations, such as LunaRich® and LunaRich X™ by Reliv and Lunasin XP® by the Scoular 
Company, which provide lunasin at levels ranging from 5 to 200 times those observed in regular 
soy protein. 
BBI-Lunasin interactions
Due to its protease inhibitory activity, BBI is stable in the human digestive system, while 
lunasin, a small peptide with no protease inhibition, is easily digested (Park et al., 2007). When 
lunasin and BBI are consumed together, as they are in naturally occurring soy protein, the 
lunasin is protected from degradation (Park et al., 2007). This observation has clinical 
significance for anti-cancer trials of Bowman-Birk Inhibitor Concentrate (BBIC). BBIC has been 
shown to reduce the incidence of breast cancer tumors in a mouse model (Hsieh et al., 2010), an 
effect originally believed to be caused by the BBI in this concentrate. However, injection with 
BBI alone generated no reduction of tumor incidence, while injection with lunasin alone caused 
significant reductions (Hsieh et al., 2010). This result suggests that BBIC is perhaps misnamed, 
as lunasin provides the bioactive anti-cancer effect in the product.
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Aside from the previously mentioned protective interaction of BBI with lunasin in the 
process of digestion, the two compounds may be linked at a more basic level in the soybean plant 
itself. A survey of lunasin concentrations detected no lunasin in a major BBI null accession of 
the perennial Glycine latifolia (de Mejia et al., 2004). As previously discussed, domesticated 
soybean lacks BBI null accessions, but significant variation in the compound has been observed, 
and other perennial Glycine species possess BBI nulls. A transgenic line has also been recently 
developed from the soybean cultivar “Asgrow 3237” that exhibits half as much chymotrypsin 
inhibition activity (Livingston et al., 2007). Lunasin levels in these BBI variants are completely 
unknown; if lunasin is found to be less prevalent or totally absent in plants with reduced levels of 
BBI, further study may reveal a common genetic or regulatory basis for the two compounds.
The associations of lunasin and BBI uncovered in these studies are of great interest to 
both medical and agricultural science. If these two compounds are associated in their beneficial 
health effects, it would be useful to select for soybean lines with appropriate amounts of both. 
Little is known about the relative levels of lunasin and BBI in soybean accessions, the genetic or 
environmental basis of these levels, or the association of the two compounds in the seed. 
Through quantifying lunasin in a number of accessions, determining the factors underlying its 
variation, and analyzing its correlation with BBI, the present study aims to offer breeders the 
information needed to develop lines for future pharmaceutical and nutraceutical enterprises. The 
objectives of this research are 1) to examine the correlation of lunasin and BBI in a number of 
soybean accessions; 2) to track the levels of lunasin and BBI over the course of seed 
development; and 3) to determine the relative importance of genotype and environment to the 
levels of lunasin and BBI in these accessions.
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Materials and Methods
Plant Information and Field Techniques
Ten soybean accessions were obtained from the USDA Soybean Germplasm Collection 
at the University of Illinois at Urbana-Champaign. These lines represented a subsample of the 
144 lines analyzed for lunasin content by de Mejia et al. (2004). Accessions were chosen from 
the lines with the highest and lowest previously observed lunasin levels for a range of maturity 
groups (MGs) to represent a high amount of diversity.
Out of the previously studied 144 lines, 10 accessions from MG III were selected to be 
grown at two locations in the summer of 2012 at the Crop Sciences Research and Education 
Center at the University of Illinois at Urbana-Champaign in Urbana, IL and a rented field near 
Bellflower, IL. These lines were chosen to represent the highest and lowest previously observed 
levels of lunasin in the maturity group and included exotic accessions from a range of 
geographical origins, including four Chinese provinces, North Korea, and South Korea, along 
with two U.S. cultivars. At the Bellflower location, two replicates of 30 seeds each from each 
accession were hand planted in rows 1.2 m long and 76 cm apart on May 16, 2012.  The same 
experiment with the same plot size was planted at the Urbana location on May 19, 2012. Fields 
were maintained with standard agronomic practices.
One MG III line, NE3399, was chosen to be studied in a time course experiment. This 
accession was selected for its relatively high yields and adaptation to central Illinois to ensure 
reliable seed production for the experiment. Seven plots of 30 seeds of NE3399 were planted in 
rows 1.2 m long and 76 cm apart at the Urbana location on May 19, 2012 and divided into two 
replications of three and a half rows each. Starting on August 9, 2012 and ending on October 8, 
2012, approximately 30 pods were harvested weekly from between the 5th and 15th nodes of 
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each of replication, with pods taken evenly from across each replication. These pods were dried 
in an oven at 40 °C for at least 72 hours, then removed and stored at room temperature until 
further use. Previous work has demonstrated the sufficiency of room temperature storage for the 
long-term stability of both BBI and lunasin (E. de Mejia, personal communication).
BBI and Lunasin Quantification by ELISA
Approximately 1 g of seed from each accession was ground into flour using a Wiley 
Intermediate laboratory mill (Thomas Scientific, NJ). Homogeneity of particle size was ensured 
by passing the flour through a 40 mesh filter, and the resulting product was stored at 4 °C until 
further use. The flour was defatted for approximately 6 hours in a Soxhlet extractor using a 
mixture of nonspectro-grade, > 85% pure hexanes (Tvap = 67.5 °C) (American Burdick & 
Jackson, Muskegon, MO) as the solvent. After defatting, the flour was allowed to air-dry in a 
fume hood overnight (14-16 h) and stored at 4 °C until used.  
Extractions were performed in triplicate on 50 mg samples of the defatted flour 
suspended in 1 mL aliquots of an extracting buffer (1% polyvinylpolypyrrolidone (PVPP) in 0.05 
M Tris-buffered saline (TBS)) (Sigma Chemical Company, St. Louis, MO) in Eppendorf 
centrifuge tubes. The Tris[hydroxymethyl]aminomethane hydrochloride (Tris-HCl) used for the 
TBS buffer solution was biotechnology performance certified, with a minimum of 99% purity. 
The samples were placed in an ultrasonic bath (Bransonic model 2510, Branson Ultrasonic 
Corporation, Danbury, CT) for 70 minutes at 40 °C; the water temperature was maintained using 
a recirculating bath (Endocal model RTE-9, Neslab Instruments, Portsmouth, NH). The samples 
were vortexed every 10 minutes during this process to ensure adequate suspension. The 
sonicated samples were then centrifuged at 20000 g for 30 min at 4 °C in an Eppendorf 
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centrifuge (model 5417R, Brinkmann Instruments, Westbury, NY), and the resulting supernatant 
was transferred to a new set of Eppendorf tubes for storage at -20 °C.
Soluble protein concentration for each sample was determined using the Protein DC-
Microplate Assay (Reagents Package 500-0116, Bio-Rad Laboratories, Hercules, CA). Samples 
were diluted 1:20 in a buffer solution (0.05 M TBS). A standard curve was prepared using 
concentrations of 1500, 1200, 900, 600, 300, 100, 30, and 10 μg/mL buffer solution of > 98% 
pure bovine serum albumin (BSA) (Sigma Chemical Company, St. Louis, MO) and measured 
along with the samples for each run. Each standard, sample, and a buffer blank was plated (5 
µl/well) in duplicate on a 96 well microtiter plate. To each well, 25 µl of reagent A (alkaline 
copper tartrate) and 200 µl of reagent B (dilute Folin reagent) were added, and the plate was 
gently agitated. After 15 minutes of incubation at room temperature, the absorbances of the plate 
were read using a photospectrometer (ELx 808 IU, Bio-Tek Instruments, Winooski, VT) at 690 
nm. Protein concentrations of the samples were determined from the values of the standard curve
derived from the protein standards.
Aliquots (100 μL) of each sample, diluted 1:50 in a buffer solution (1% Tween in 0.05 M 
TBS), were coated on the wells of a Nunc Maxisorp 96 well plate specifically designed for 
ELISA use. A standard curve of pure synthetic BBI or pure synthetic lunasin (FilGen 
BioSciences, Fairfield, CA), consisting of at least 6 concentrations from 8 to 100 ng/mL and 
prepared in the same buffer solution, was plated along with the samples for each run. These 
standards were plated in triplicate, samples were plated in duplicate, and blanks were plated in at 
least duplicate. All three extractions for each sample were run on the same plate to provide 
duplication.
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Coated plates were incubated at 4 °C overnight (14-16 h), then washed 6 times using 300 
μL of washing solution (0.05% Tween-20 in 0.01 M PBS) (Sigma Chemical Company, St. 
Louis, MO) at a dispensing rate of 150 μL/well/s and an aspiration rate of 5 mm/s. This 
phosphate buffered saline (PBS) with polyoxyethylene sorbitan monolaurate (Tween 20) buffer 
was mixed from packets with the proper concentrations and pH (0.01 M PBS, 0.05% Tween 20, 
pH 7.4) pre-measured. The plates were then blocked with 300 μL/well of a BSA blocking 
solution (5% BSA and 1% Tween in 0.05M TBS) and allowed to incubate at room temperature 
for 1 h. After blocking, the plates were washed again using the same protocol. 
For BBI quantification, 50 μL of a 1:1000 dilution of mouse-derived monoclonal BBI 
antibody (Agdia, Inc., Elkhart, IN) in a BSA buffer solution (3% BSA and 1% Tween in 0.05 M 
TBS) were then added to each well, and the plates were incubated for another hour. Following 
another wash, 50 μL of a 1:2000 dilution of alkaline phosphatase conjugate anti-mouse IgG 
secondary antibody in the BSA buffer solution were added to each well. For lunasin 
quantification, 50 μL of a 1:100 dilution of rabbit-derived monoclonal lunasin antibody 
(provided by Dr. Benito de Lumen, University of California, Berkley) in a BSA buffer solution 
(3% BSA and 1% Tween in 0.05 M TBS) were added, and after incubation and washing, 50 μL 
of a 1:1000 dilution of alkaline phosphatase conjugate anti-rabbit IgG secondary antibody in the 
BSA buffer solution were added to each well. 
For both BBI and lunasin quantification, the plates were again incubated for an hour at 
room temperature and washed according to the described protocol. Development of the plates 
was conducted using 100 μL/well of p-nitrophenyl phosphate (pNPP, Sigma N-7653), the color 
substrate for alkaline phosphatase. After 20 minutes of incubation at room temperature, the 
plates were read in an ELISA plate reader (ELx 808 IU, Bio-Tek Instruments, Winooski, VT) at 
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405 nm. The development reaction was stopped at 30 minutes using 100 μL/well of 3 N NaOH, 
and the plates were read again at 35 minutes.
Standard curves were obtained from the average of at least two ELISA replications. 
Absorbances for BBI were converted into mg/g defatted flour using the standard curve 
y = .0119x + .0613, and absorbances for lunasin were converted using the standard curve
y = .0011x + .1428. The data were analyzed using analysis of variance (ANOVA), Tukey’s range 
test, correlation, and linear regression in SAS 9.1 (SAS Institute Inc., 2003). 
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Results and Discussion
Significant differences (Table 1; F = 3.75, p = .03) did exist among the entries grown in 
the field for BBI concentrations. Tukey’s range test was used to separate the entries into classes 
based on BBI concentration (Table 2). It was determined that the highest BBI levels were 
observed in the cultivar Lincoln, followed by Jogun and A.K. (Harrow). The lowest BBI levels 
were seen in PI 567362A (Ningxia, China) and PI 567775A (Jiangsu, China). The observation of 
significant BBI variation among the entries supports the conclusions of the previous literature. 
Gladysheva et al. (2000) found a threefold difference in BBI between the highest and lowest 
levels among 9 entries, similar to the range reported here, and Pesic et al. (2007) also detected 
significant differences in BBI levels among a set of 12 Serbian soybean lines.
Table 1. ANOVA table for BBI concentrations among diverse soybean entries grown at two 
locations in Illinois in 2012.
Source Sum of Squares DF Mean Squares F value p value
Environment .000847 1 .000847 0.15 0.71
Entry .195781 9 .021753 3.75 0.03
Environment x Entry .052153 9 .005795 3.42 0.01
Residual .032209 19 .001695 . .
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Table 2. Average BBI and lunasin concentrations among diverse soybean entries grown at two 
locations in Illinois in 2012. Different letters in the same column indicate significantly different 
means as determined by Tukey’s range test (p < .05).




PI 567775 A China .101 a 2.64 a
PI 567362 A China .119 a 2.39 a
PI 398261 Korea .148 ab 4.06 b
PI 594871 China .149 ab 4.17 b
NE3399 USA .155 ab 3.26 ab
PI 594444 B China .165 ab 2.93 ab
PI 603167 China .203 abc 3.99 b
A.K. (Harrow) China .251 bcd 3.67 ab
Jogun Korea .295 cd 3.18 ab
Lincoln USA .319 d 3.51 ab
There was also a significant interaction effect of entry and environment on BBI 
concentration (Table 1; F = 3.42, p = .01). Using contrasts to separate the interaction effect, it 
was determined that Lincoln and A.K. (Harrow) contained significantly more BBI (Table 3; F = 
5.58, p = .03; F = 8.04, p = .01) at the Urbana location than at the Bellflower location, while 
Jogun contained significantly more BBI (Table 3; F = 11.62, p < .01) at Bellflower than at 
Urbana. Krishnan et al. (2012), however, found no interaction between location and entry for 
BBI levels. Interestingly, the three entries with the highest BBI concentrations in this study were 
also the only entries with significant interaction effects, but these interactions, as previously 
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noted, were not same for all three entries. However, none of the genotypes used in the present 
study were tested by Krishnan et al. (2012), so a direct comparison cannot be made. Further 
research with more genotypes and better environmental data might more accurately determine 
the presence or absence of a genotype by environment interaction effect on BBI variation.
Table 3. Significance of environment x entry interaction for BBI concentration among diverse 
soybean entries grown at two locations in Illinois in 2012.
Entry Numerator DF Denominator DF F value p value
PI 603167 1 19 0.74 0.40
Lincoln 1 19 5.58 0.03
PI 594444 B 1 19 0.50 0.49
Jogun 1 19 11.62 < 0.01
PI 567362 A 1 19 0.02 0.88
PI 594871 1 19 1.95 0.18
PI 567775 A 1 19 0.08 0.78
NE3399 1 19 2.39 0.14
AK(Harrow) 1 19 8.04 0.01
PI 398261 1 19 0.12 0.73
Although there were significant entry x environment interactions, no significant main 
effect for environment on BBI (Table 1; F = .15, p = .71) was observed in the field experiment, a 
result in contrast with that of Krishnan et al. (2012). These authors grew 8 soybean lines in 3 
locations and detected a consistent environmental effect on BBI, as measured by immunoblot 
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analysis. The previous paper was, however, unable to determine what environmental differences 
generated the significant effect; although soil analyses eliminated differences in available sulfur 
or nitrogen as causative factors, temperatures and moisture levels at the different locations were 
not reported. It is therefore difficult to conclude to what factor the significant environmental 
main effect may have been attributed, and conversely, to conclude if the environments of the 
present study did not differ for that factor.
The BBI concentrations observed in the present study are within the range of previously 
reported values. Yeboah et al. (1996) reported a yield of .185 mg BBI/g defatted flour using a 
rapid purification method, while Gladysheva et al. (2000) found a value of .23 mg BBI/g 
defatted flour; both values are relatively close to the average BBI concentration of .191/g 
defatted flour observed across the field experiment. 
Significant differences also existed among entries in the field experiment for levels of 
lunasin (Table 4; F = 6.09, p = .01). Tukey’s range test was used to separate the entries into 
classes based on lunasin concentration (Table 2): PI 603167 (North Korea), PI 594871 (Yunnan, 
China), and PI 398261 (Kyonggi, South Korea) had the highest lunasin levels of the entries, 
while PI 567362A and PI 567775A had the lowest levels. Interestingly, these two entries also 
had the lowest observed BBI levels in the present study. The remaining entries were not 
significantly different from either of these two classes. The observation of significant lunasin 
variation among entries corroborates the previous results of Vasconez (2004) and Wang et al.
(2008). Vasconez (2004) indicated that genotypes of Chinese origin may contain more lunasin on 
average than genotypes from the Korean Peninsula; this effect did not appear to be supported in 
the present work, as both of the lowest-lunasin entries came from China and two of the highest-
lunasin entries came from the Korean Peninsula. However, the previous work had also shown 
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greater lunasin variability within these regions than between them, so a failure to detect similar 
differences due to geographical origin with the present study’s relatively small sample size 
should not be entirely unexpected.
Table 4. ANOVA for lunasin concentrations among diverse soybean entries grown at two 
locations in Illinois in 2012.
Source Sum of Squares DF Mean Square F value p value
Environment 79.470132 1 79.470132 301.86 < 0.01
Genotype 14.440088 9 1.604454 6.09 0.01
Environment x 
Genotype
2.369423 9 .263269 1.00 0.47
Residual 4.997216 19 .263011 . .
The main effect of environment on lunasin in the field experiment was highly significant 
(Table 4; F = 301.86, p < .0001), with concentrations at the Bellflower location averaging less 
than half (1.92 mg/g defatted flour) those at the Urbana location. The importance of environment 
to lunasin variation is further supported by the lack of similarity between the lunasin values of 
the present study and those of Vasconez (2004) for the same genotypes. The seeds in that 
previous work were obtained directly from the USDA Soybean Germplasm Collection, which, as 
previously discussed, is maintained by growing out a portion of its accessions every year. This 
practice means that the samples for each genotype used in the previous study were grown in 
different environmental conditions from each other and from the seeds analyzed in the field 
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experiment. The rankings of the entries for lunasin were different between the Vasconez study 
(2004) and the present study, suggesting that environment is more important than genetic 
differences in determining the amount of lunasin present in soybean.
The lunasin concentrations of the field experiment are within the range reported in the 
existing literature, but the concentrations at Bellflower fall far below the average of the 19 
previously reported MG III genotypes (Vasconez, 2004), and some entries had lunasin 
concentrations below the previous minimum value (1.9 mg/g) reported for MG III. As previously 
discussed, de Mejia et al. (2004) reported a range of 1 to 13.3 mg lunasin/g defatted flour across 
a diverse array of soybean genotypes, and the cultivars grown in greenhouse conditions by Wang 
et al. (2008) ranged from 5.7 to 11.4 mg lunasin/g defatted flour. The average lunasin 
concentrations for the entries in this study range from 2.39 to 4.17 mg/g defatted flour, and the 
MG III plants grown at the Urbana location had an average lunasin concentration of 4.77 mg/g 
defatted flour, nearly identical to the value reported for the MG III genotypes (4.7 mg/g defatted 
flour) by de Mejia et al. (2004), which had also been grown in Urbana. 
However, environmental conditions have previously been associated with differences in 
lunasin concentration of similar magnitude to those observed between Bellflower and Urbana, as 
reported by Wang et al. (2008). For example, when grown under high temperature and low 
moisture, the cultivar Imari yielded only 5.36 mg lunasin/g defatted flour, but when grown at an 
intermediate temperature with high moisture, the same cultivar yielded 9.36 mg/g, a difference of 
4 mg/g. This proportional difference (~43%) due to environment is similar to that observed in the 
present work. Of particular interest to the present study are the differences recorded for the 
cultivar Jack. This cultivar yielded 11.40 mg lunasin/g defatted flour under intermediate 
temperature and low moisture but only 7.85 mg/g when grown at intermediate temperature and 
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high moisture. Over the growing season of the present study, rainfall at Urbana was 
approximately 33% less than that at Bellflower (Table 5) (wunderground.com); although this 
difference is less than that between the low and high moisture conditions (70%) employed in the 
previous work, it is a significant reduction in available moisture, and plants grown at Urbana 
yielded significantly more lunasin. Both environments had similar average temperatures over the 
growing season, suggesting that soil moisture was the driving factor behind the observed 
differences.













May 20 63 21 62
June 23 49 21 7
July 27 34 27 1
August 22 173 23 112
September 17 202 18 148
October 10 163 11 123
The consistency of the lower lunasin values at Bellflower is perhaps of the greatest 
interest, as previous work has indicated that different genotypes respond in different directions to 
the same change in environmental conditions. According to Wang et al. (2008), both the 
genotype by temperature and genotype by soil moisture interactions for lunasin concentration 
were significant, but the genotype by environment interaction in the present study was not 
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significant (Table 3; F = 1.00, p = .4719). Without exception, every entry contained less lunasin 
at Bellflower than at Urbana. However, it is possible that the variability of external factors (e.g., 
disease pressure, microenvironmental differences) introduced by a field experiment may have 
influenced these interactions, and caution must be exercised in the comparison of greenhouse and 
field data. Further experimentation using greenhouse controls and a greater number of genotypes
will be necessary to determine the most common pattern of lunasin’s response to environmental 
factors and which of these factors are most important.
Despite the existing information about lunasin’s properties and presence in soybean, its 
biological role in the plant remains unknown. Some of the data obtained in this study may offer a 
hypothesis for its function. Lunasin was observed at higher concentrations in the more water-
stressed environment of Urbana; water stress is known to generate an excess of reactive oxygen 
species (ROS) in plants (Iturbe-Ormaetxe et al., 1998; Lima et al., 2002), which can lead to 
significant oxidative damage of key cellular components. Nuclear DNA can be harmed by ROS, 
and although plants have a number of mechanisms to repair (Britt, 1996) or resist (Badawi et al., 
2004) this damage, it may reach unsustainable levels in some cells. In this case, the plant often 
resorts to programmed cell death in the damaged cells (Foyer & Noctor 2005). Lunasin has been 
shown to encourage apoptosis in cancerous cells, many of which also are derived through DNA 
damage from oxidative stress (Valko et al., 2006). In the developing soybean seed, lunasin may 
serve to target the elimination of defective cells under drought conditions, ensuring the normal 
development of these vital propagules. It is reasonable that regulatory mechanisms would exist in 
some soybean cultivars to increase lunasin under drought conditions if the peptide does indeed 
provide this function. This line of reasoning is highly speculative, but would serve to explain 
some of the results of the present experiments. Future work might examine metabolic variables 
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in soybean genotypes with diverse lunasin contents or apply pure lunasin to drought-stressed 
cells to determine if this hypothesis has merit.
The results for BBI and lunasin concentration at each of the harvest dates in the time 
course experiment are presented in Table 6, organized by sampling date. The highest level of 
BBI (.21 mg/g defatted flour) was observed at the 5th week of sampling, and the highest level of 
lunasin (4.85 mg/g defatted flour) was observed at the 4th week of sampling. A visual 
representation of the levels of the two compounds over the experiment is given in Figure 1. A 
significant correlation was detected between BBI and lunasin concentrations (Figure 2; R2 = 
.6396, F = 12.42, p = .0097) over the time course, hinting at a similar regulatory mechanism or 
set of mechanisms governing their levels in the growing soybean. The lack of a significant 
correlation between either BBI (R2 = .1763, F = 1.5, p = .2605) or lunasin (R2 = .2793, F = 2.71, 
p = .1436) with overall protein is of particular interest, as this result suggests that BBI and 
lunasin are governed by factors beyond the general increase in protein associated with seed fill.
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Table 6. Average BBI, lunasin, and soluble protein concentrations over 9 weeks for NE3399
grown at one location in Illinois in 2012.
Calendar Date BBI (mg/g defatted 
flour)
Lunasin (mg/g defatted flour) Soluble Protein 
(mg/g defatted 
flour)
8-9 0.00 0.57 76
8-17 0.01 1.47 101
8-24 0.03 3.05 107
8-31 0.19 4.85 148
9-7 0.21 3.46 185
9-14 0.20 3.87 136
9-21 0.10 2.93 246
9-28 0.09 3.75 223
10-8 0.12 3.61 240
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Figure 1. Average BBI and lunasin concentrations over 9 weeks for NE3399 grown at 
one location in Illinois in 2012. Error bars indicate the standard error of the means for lunasin 
and for BBI.
Both BBI and lunasin peak around the 4th or 5th week of the time course, approximately 
the R6 stage of seed development, then decrease and maintain a lower concentration while 
overall protein continues to increase. The Western blot method used by Park et al. (2005) was 
not as sensitive as the ELISA method employed in the present study, but these authors also 
detected peak concentrations of BBI and lunasin sometime before the end of seed development 
and a subsequent decline. BBI associates with the 2S soybean protein fraction (Wolf, 1970), and 
lunasin has also been shown to belong to this fraction (Seber et al., 2012). In previous work, the 
2S fraction has been shown to increase early in seed development before reaching a plateau (Hill 












































present in the 2S fraction, this result is consistent with the finding that the two compounds do not 
increase linearly throughout the entirety of soybean seed development.
Figure 2. Significant correlation of average BBI and lunasin over 9 weeks among diverse 
soybean entries grown at one location in Illinois in 2012. Vertical error bars indicate standard 
error of the mean for lunasin at each harvest date. Horizontal error bars indicate standard error of 
the mean for BBI at each harvest date.
As previously discussed, lunasin may serve as a drought protective mechanism in 
actively developing seeds. It may be supposed that once the soybean seed is no longer actively 
developing, the need for protection from DNA damage would be reduced, and lunasin levels 
might decrease, as was observed in the time course experiment. Similarly, BBI may also serve a 
protective role in soybean as an insect deterring (Ryan, 1990) or even insecticidal (Prasad et al., 
33
2010) agent. Although BBI has not been shown to be induced by insect wounding in soybean, 
members of the BBI family have shown this response in other species. The first wound-inducible 
BBI was observed in alfalfa (Brown et al., 1985), and subsequent molecular work has shown that 
transcripts for BBI family proteins accumulate after wounding in both maize (Eckelcamp et al., 
1993) and rice (Qu et al., 2003). As with drought protection, insect protection is likely more 
important in plants undergoing the metabolically intense process of seed fill. Therefore, it would 
be advantageous to accumulate BBI and lunasin during active seed fill, but the plant might make 
better use of the nutrients (especially those of the sulfur-rich BBI) elsewhere later in the season 
and break down the compounds for remobilization. Again, the present study lacks the data to 
support or refute this hypothesis, but future work might examine the impacts of insect pressure 
on BBI induction and accumulation in soybean to illuminate this issue.
Although the relative levels of BBI and lunasin in the developing seed may be 
significantly correlated, the absolute levels of the two compounds seem to be independent across 
the studied genotypes. There appeared to be little relationship between the lunasin and BBI 
concentrations observed in the field experiment. To this researcher’s knowledge, this is the first 
study to compare BBI and lunasin levels among soybeans grown in common environments. 
Additionally, no relationship between the BBI levels of the accessions taken from the USDA 
Soybean Germplasm Collection and the lunasin levels reported by Vasconez (2004) for the same 
accessions was observed (Table 7). The seed sources used in the previous work were all different 
from those used in the present study and were grown under different environmental conditions in 
different years (R. Nelson, personal communication). These results emphasize the importance of 
environment to BBI and lunasin and suggest that reliable testing for genotypic differences in 
34
concentrations of the two compounds must be conducted under constant environmental 
conditions.
Lunasin’s biological role is unknown, but it is not thought to be insecticidal like BBI. 
Therefore, if pest pressure is a significant selective force on BBI, and there is no linkage between 
the genes for BBI and lunasin (as is likely; none of the BBI family sequences reported by de 
Almedia Barros et al. (2012) are present on chromosome 13, the location of the lunasin sequence 
as reported by Grant et al. (2010)), BBI would be selected for independently of lunasin.
Table 7. Maturity group, geographical origin, and average BBI concentrations for entries 
taken from the USDA Soybean Germplasm Collection and average lunasin concentrations for the 
same entries as reported by Vasconez (2004).
Entry Maturity 
Group




Cisne IV USA 0.12 7.56
PI 587670B VII China 0.26 8.51
PI 603309 I China 0.27 2.19
PI 228056 VIII Japan 0.28 2.22
PI 90243 V Korea 0.32 1.87
PI 603334 0 China 0.34 2.22
PI 507298 VI Japan 0.36 1.90
FC 33243 IV Unknown 0.37 7.58
Council 0 USA 0.38 7.41
PI 424474-1 VII Korea 0.38 2.41
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The apparent independence of BBI and lunasin is useful information for breeders who 
may wish to improve soybeans for the nutraceutical market. The value of BBI in protecting 
lunasin from digestion has been established (Park, 2007), and breeding efforts would be 
necessary to increase the levels of each compound independently. However, the genetic variation 
observed for both compounds in the present study suggests that there exists sufficient diversity in 
the germplasm for breeders to make significant gains. Conversely, the environmental variation 
seen for lunasin concentrations is promising for companies that wish to extract the peptide alone. 
Sourcing soybeans from drought-stressed areas may allow for more lunasin to be derived from 
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